Scilex Holding (SCLX) Free Cash Flow Growth (3y) (2023 - 2026)
Scilex Holding (SCLX) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
41.47% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-15.10% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-3.92% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
30.35% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
106.58% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
27.06% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
14.07% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
210.20% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
27.23% |
| 10 |
Scilex Holding |
54.30 Mn |
-95.62 Mn |
4.15 Mn |
28.39% |
| Date | Value |
|---|
| Mar 31, 2026 |
28.39% |
| Dec 31, 2025 |
-188.84% |
| Sep 30, 2025 |
47.99% |
| Jun 30, 2025 |
37.07% |
| Mar 31, 2025 |
36.79% |
| Dec 31, 2024 |
27.87% |
| Sep 30, 2024 |
236.23% |
| Jun 30, 2024 |
83.60% |
| Mar 31, 2024 |
175.88% |
| Dec 31, 2023 |
-1,516.61% |
